Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

April 23 2018 Buprenorphine has been found to have lower rates of overdose death than methadone...

Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

March 29 2018 Mefloquine is safe to use for malaria prevention during pregnancy, a Cochrane...

  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48
  • Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Monday, 23 April 2018 16:48
  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:27
  • Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Thursday, 29 March 2018 11:21

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a syringe imageApril 23 2018

Buprenorphine has been found to have lower rates of overdose death than methadone when used in opioid substitute therapy. The impact was particularly seen in the first four weeks of treatment, researchers from the University of Bristol have found.

Data from 11,000 GP practices indicated that buprenorphine was prescribed for approximately a third of opioid substitution patients, while methadone was used in two-thirds of cases.

“Patients on buprenorphine had substantially lower rates of overdose death during treatment compared to those on methadone: four times lower in the first 4 weeks (0.3% compared with 1.24%) and almost twice as low during the rest of time on treatment (0.18% compared with 0.33%). These differences remained even after adjusting for differences in patient and practice characteristics for those prescribed methadone or buprenorphine,” said the National Institute for Health Research.

“Patients on buprenorphine also had lower rates of all-cause mortality during and immediately after treatment – which may be because patients who are older and have other physical and mental health complications may do better on buprenorphine than methadone.”

Although numbers of patients in opioid substitution therapy are at record levels, the number of drug-related deaths is continuing to rise.

Professor Matthew Hickman, from the NIHR Health Protection Research Unit and Population Health Sciences at University of Bristol, was one of the lead authors of the study published in Addiction. “Our research provides evidence to support a change in the way treatment is delivered that could save lives,” he said. 

“We now need trials in the UK on how we combine different opioid substitution treatments alongside other behaviour change interventions to retain people in treatment long enough to reduce the number of drug related deaths in the population.”

Links:
NIHR announcement    
M Hickman et al. ‘The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom’. Addiction. Published online April 19 2018.   

Clinical News

May 23 2018 The Court of Appeal has commenced hearing a case around the Government’s cut in pharmacy funding and other changes to community pharmacy introduced in 2016.
May 21 2018  NHS England and Capita’s handling of primary care support services has been criticised in an official report. The National Audit Office has published a review saying that “NHS England and...